CH Biotech R&D Balance Sheet Health
Financial Health criteria checks 6/6
CH Biotech R&D has a total shareholder equity of NT$2.6B and total debt of NT$563.4M, which brings its debt-to-equity ratio to 21.5%. Its total assets and total liabilities are NT$3.6B and NT$951.2M respectively. CH Biotech R&D's EBIT is NT$477.6M making its interest coverage ratio -150.2. It has cash and short-term investments of NT$598.4M.
Key information
21.5%
Debt to equity ratio
NT$563.36m
Debt
| Interest coverage ratio | -150.2x |
| Cash | NT$598.36m |
| Equity | NT$2.62b |
| Total liabilities | NT$951.24m |
| Total assets | NT$3.57b |
Recent financial health updates
CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt
Apr 05
Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?
Dec 15
Recent updates
CH Biotech R&D (GTSM:6534) Takes On Some Risk With Its Use Of Debt
Apr 05A Look At CH Biotech R&D's (GTSM:6534) Share Price Returns
Mar 18Are CH Biotech R&D Co., Ltd.'s (GTSM:6534) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Feb 09Returns On Capital At CH Biotech R&D (GTSM:6534) Paint An Interesting Picture
Jan 11Does CH Biotech R&D (GTSM:6534) Have A Healthy Balance Sheet?
Dec 15Tread With Caution Around CH Biotech R&D Co., Ltd.'s (GTSM:6534) 1.8% Dividend Yield
Nov 24Financial Position Analysis
Short Term Liabilities: 6534's short term assets (NT$814.3M) exceed its short term liabilities (NT$586.9M).
Long Term Liabilities: 6534's short term assets (NT$814.3M) exceed its long term liabilities (NT$364.3M).
Debt to Equity History and Analysis
Debt Level: 6534 has more cash than its total debt.
Reducing Debt: 6534's debt to equity ratio has reduced from 67.4% to 21.5% over the past 5 years.
Debt Coverage: 6534's debt is well covered by operating cash flow (87.6%).
Interest Coverage: 6534 earns more interest than it pays, so coverage of interest payments is not a concern.